Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

andidate development.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' dependence on sales of Xyrem, and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; the uncertain and time-consuming clinical development and regulatory process for its product candidates, including its intranasal clonazepam product candidate; regulatory risks; Jazz Pharmaceuticals' cash flow estimates, the sufficiency of its cash resources; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its quarterly report on Form 10-Q for the quarter ended September 30, 2010 filed with the Securities and Exchange Commission on November 5, 2010.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009 Revenues: Product sales, net

$
52,357$
37,319$ 170,006$ 115,108 Royalties, net

7286812,6372,203 Contract revenues

2842841,13811,138 Total revenues

53,36938,284173,781128,449 Operating expense
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... , SAN DIEGO, Sept. 8 ... ("Stemedica"), a world leader in stem cell research and manufacturing, ... and Trademark Office ("USPTO") for a proprietary methodology in the ... the USPTO on August 27th of this year. The ...
... MELBOURNE, Australia, Sept. 3 Cytopia Limited,s (ASX: CYT) ... Food and Drug Administration (FDA) review. CYT387 is a small-molecule ... The company,s IND application is now active and Cytopia is ... United States. , , CYT387 will be ...
Cached Medicine Technology:United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 2United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 3Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2
(Date:9/21/2014)... 21, 2014 Hundreds of Risperdal ... in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein ... proceeding’s next monthly meeting has been scheduled for ... , “Our Firm is representing a number of ... litigation. We are pleased with its continued progress,” ...
(Date:9/21/2014)... 2014 (HealthDay News) -- Young women starting college understand ... foods they should eat. But they aren,t confident they ... to a new study. The study involved ... Illinois,s Peer Education Exercising and Eating Right program. The ... choose to eat if they were very busy with ...
(Date:9/21/2014)... 2014 Discount-Dress.com, a company ... recently announced its decision to implement a new shopping ... for ladies across the world. Furthermore, the company has ... ladies. , The new items come in fashionable ... prices, up to 56 percent off. "We are happy ...
(Date:9/21/2014)... Dallas, TX (PRWEB) September 21, 2014 ... and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 ... on Global and Chinese Fenofibrate (CAS 49562-28-9) ... information of Fenofibrate (CAS 49562-28-9) including its ... explores global and China’s top manufacturers of ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 High in ... teams of disabled and able-bodied athletes rafted the Colorado ... a ropes course in pursuit of outdoor adventure. At ... national non-profit World T.E.A.M. Sports, disabilities proved to be ... successfully completed the three stage event. , Each participating ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... LLC has joined the effort to help relieve ... of Cyclone Nargis. Special donation kiosks,have been developed ... the,virtual world of Second Life, with coordination being ... island,( http://slurl.com/secondlife/Simuality/106/83/41 )., In addition, links to ...
... Coalition for Iraq and Afghanistan Veterans Gather in Virginia ... Organizations, CHANTILLY, Va., May 9 As the ... death toll climbs above 4,000 and,casualty numbers approach the ... organizations on the homefront have organized to help,bereaved families ...
... disease-resistant gene wards off fusarium wilt on leaves , , ... to helping tomatoes fight a fungus that causes wilt ... there,s an ongoing battle against the ability of plant ... system, according to background information in the study. One ...
... demands reap mental benefits regardless of age or ... News) -- Having an intellectually demanding job that ... abilities during retirement, regardless of intelligence, education level ... suggests. , "Our society is expected to live ...
... wanted minimally invasive procedure more often, despite drawbacks , , ... be trumping science when it comes to treatments for ... patients are getting a newer, minimally invasive surgery, because ... though there is little data on actual differences in ...
... From Bush Administration,s $770 Million Cut to,Medicare-Financed Nursing Home ... the,American Health Care Association (AHCA) and Alliance for Quality ... release and comment on a,new study from The Lewin ... from the Bush Administration,s recently-announced cut of,$770 million to ...
Cached Medicine News:Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Demanding Jobs May Pay Cognitive Dividends in Retirement 2Health News:Newer Prostate Cancer Treatment Similar to Traditional Surgery 2Health News:Newer Prostate Cancer Treatment Similar to Traditional Surgery 3
... Plate Shaker are designed to give reliable performance ... microplates. The on/off button, power supply socket and ... of the unit. The speed knob is located ... of speed from a minimum 950 rpm to ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
Modular flow cytometer with all options....
Medicine Products: